Head-to-head · free
Arbutus Biopharma Corp vs Baxter International Inc.
ABUS vs BAX — return on capital, cash generation, margins and balance sheet side by side.
ABUS
3 / 6
measures where ABUS leads
BAX
3 / 6
measures where BAX leads
A simple count of which company scores better on each measure — not a recommendation to buy or sell.
| Measure | ABUS · FY2025 | BAX · FY2025 |
|---|---|---|
| Revenue | $14.1M | $11.2B |
| Net income | (33.5M) | (957.0M) |
| Revenue growth (yearly, multi-year) | 6.4% | -3.2% |
| Free cash flow | (39.6M) | — |
| Free cash flow margin | -281.5% | — |
| Net cash / (debt) | — | — |
| ROIC | — | — |
| Return on equity | -38.5% | -14.6% |
| Gross margin | — | 30.1% |
| Operating margin | -192.1% | 1.6% |
| Net debt / EBITDA | 0.48x | 11.16x |
Figures are as reported by each company; latest fiscal year shown.
Where Arbutus Biopharma Corp's cash went (FY2025)
- Capital spending
- $0
- Buybacks
- —
- Dividends
- —
- Acquisitions
- —
- Net debt issued / (repaid)
- —
Where Baxter International Inc.'s cash went (FY2025)
- Capital spending
- —
- Buybacks
- —
- Dividends
- —
- Acquisitions
- —
- Net debt issued / (repaid)
- —
Ask which business is stronger
"Which one reinvests at higher returns?" "Who carries more risk in its filings?" Get answers drawn straight from both companies' filings.
Compare them free